Canada markets open in 8 hours 44 minutes

Satellos Bioscience Inc. (MSCL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.2500-0.0100 (-3.85%)
At close: 03:54PM EST
Full screen
Previous Close0.2600
Open0.2550
Bid0.2500 x N/A
Ask0.2650 x N/A
Day's Range0.2500 - 0.2550
52 Week Range0.2200 - 1.3600
Volume18,500
Avg. Volume42,633
Market Cap10.449M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6040
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

    Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, a

  • Newsfile

    Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development

    -Proof of concept studies to be completed by YE- Toronto, Ontario--(Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has created, prioritized and advanced novel small molecule drug candidates into further preclinical studies.The Company's compounds have been

  • Newsfile

    Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting

    - Advancements on the Company's evaluation of potential new disease indication Toronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that Ryan Mitchell, PhD and Director of Business Development will present preliminary preclinical proof of concept d